Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps – GSK
GSK plc announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with intranasal corticosteroids… read more.
